Wegovy (semaglutide), a licensed GLP-1 receptor agonist approved by the MHRA for chronic weight management, has demonstrated significant efficacy in clinical trials
For many older adults, its the first opportunity to get GLP-1s, short for glucagon-like peptide-1 receptor agonists, covered by insurance when used strictly for weight loss
Weighing the GLP-1 Market Now theres a report by Goldman, if youre really interested in digging in, they talk about GLP-1s quite extensively
For example, naltrexone doses for treating alcohol use disorder range from 50 mg daily to 100 mg daily
253 Drugs that activate GLP-1 receptors, known as GLP-1 receptor agonists (GLP1-RAs), are used to treat type 2 diabetes
Wegovy should be injected into the skin on your upper arms, thigh, or tummy (abdomen)